Urease-powered nanobots for radionuclide bladder cancer therapy

Cristina  Simó Costa; Meritxell Serra-Casablancas; A. C. L. Hortelão; Valerio Di Carlo; Sandra Guallar Garrido; Sandra Plaza-García; Rosa Maria Rabanal; Pedro Ramos-Cabrer; Balbino Yagüe; Laura Aguado; Lídia Bardia; Sébastien Tosi; Vanessa Gómez Vallejo; Abraham Martín; Tania Patino; Esther Julián; Julien Colombelli; Jordi Llop; Samuel Sánchez

doi:10.1038/s41565-023-01577-y

Urease-powered nanobots for radionuclide bladder cancer therapy

Cristina Simó Costa , Meritxell Serra-Casablancas, A. C. L. Hortelão, Valerio Di Carlo, Sandra Guallar Garrido, Sandra Plaza-García, Rosa Maria Rabanal, Pedro Ramos-Cabrer, Balbino Yagüe, Laura Aguado, Lídia Bardia, Sébastien Tosi, Vanessa Gómez Vallejo, Abraham Martín, Tania Patino, Esther Julián, Julien Colombelli, Jordi Llop, Samuel Sánchez

Research output: Contribution to journal › Article › Research › peer-review

59 Citations (Scopus)

Abstract

Bladder cancer treatment via intravesical drug administration achieves reasonable survival rates but suffers from low therapeutic efficacy. To address the latter, self-propelled nanoparticles or nanobots have been proposed, taking advantage of their enhanced diffusion and mixing capabilities in urine when compared with conventional drugs or passive nanoparticles. However, the translational capabilities of nanobots in treating bladder cancer are underexplored. Here, we tested radiolabelled mesoporous silica-based urease-powered nanobots in an orthotopic mouse model of bladder cancer. In vivo and ex vivo results demonstrated enhanced nanobot accumulation at the tumour site, with an eightfold increase revealed by positron emission tomography in vivo. Label-free optical contrast based on polarization-dependent scattered light-sheet microscopy of cleared bladders confirmed tumour penetration by nanobots ex vivo. Treating tumour-bearing mice with intravesically administered radio-iodinated nanobots for radionuclide therapy resulted in a tumour size reduction of about 90%, positioning nanobots as efficient delivery nanosystems for bladder cancer therapy.

Original language	English
Pages (from-to)	554-564
Number of pages	19
Journal	Nature Nanotechnology
Volume	19
Issue number	4
Early online date	15 Jan 2024
DOIs	https://doi.org/10.1038/s41565-023-01577-y https://doi.org/10.1038/s41565-023-01577-y
Publication status	Published - 15 Jan 2024

Keywords

Cell
Drug-delivery
Nanomotors
Tissue
Tumor penetration
Animals
Urinary Bladder Neoplasms/diagnostic imaging
Mice
Urease
Administration, Intravesical
Radioisotopes/therapeutic use

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://ddd.uab.cat/record/310544

Cite this

Simó Costa , C., Serra-Casablancas, M., Hortelão, A. C. L., Carlo, V. D., Garrido, S. G., Plaza-García, S., Rabanal, R. M., Ramos-Cabrer, P., Yagüe, B., Aguado, L., Bardia, L., Tosi, S., Vallejo, V. G., Martín, A., Patino, T., Julián, E., Colombelli, J., Llop, J., & Sánchez, S. (2024). Urease-powered nanobots for radionuclide bladder cancer therapy. Nature Nanotechnology, 19(4), 554-564. https://doi.org/10.1038/s41565-023-01577-y, https://doi.org/10.1038/s41565-023-01577-y

@article{40f769bca2014ecea52189279c5d922f,

title = "Urease-powered nanobots for radionuclide bladder cancer therapy",

abstract = "Bladder cancer treatment via intravesical drug administration achieves reasonable survival rates but suffers from low therapeutic efficacy. To address the latter, self-propelled nanoparticles or nanobots have been proposed, taking advantage of their enhanced diffusion and mixing capabilities in urine when compared with conventional drugs or passive nanoparticles. However, the translational capabilities of nanobots in treating bladder cancer are underexplored. Here, we tested radiolabelled mesoporous silica-based urease-powered nanobots in an orthotopic mouse model of bladder cancer. In vivo and ex vivo results demonstrated enhanced nanobot accumulation at the tumour site, with an eightfold increase revealed by positron emission tomography in vivo. Label-free optical contrast based on polarization-dependent scattered light-sheet microscopy of cleared bladders confirmed tumour penetration by nanobots ex vivo. Treating tumour-bearing mice with intravesically administered radio-iodinated nanobots for radionuclide therapy resulted in a tumour size reduction of about 90%, positioning nanobots as efficient delivery nanosystems for bladder cancer therapy.",

keywords = "Cell, Drug-delivery, Nanomotors, Tissue, Tumor penetration, Animals, Urinary Bladder Neoplasms/diagnostic imaging, Mice, Urease, Administration, Intravesical, Radioisotopes/therapeutic use",

author = "{Sim{\'o} Costa}, Cristina and Meritxell Serra-Casablancas and Hortel{\~a}o, {A. C. L.} and Carlo, {Valerio Di} and Garrido, {Sandra Guallar} and Sandra Plaza-Garc{\'i}a and Rabanal, {Rosa Maria} and Pedro Ramos-Cabrer and Balbino Yag{\"u}e and Laura Aguado and L{\'i}dia Bardia and S{\'e}bastien Tosi and Vallejo, {Vanessa G{\'o}mez} and Abraham Mart{\'i}n and Tania Patino and Esther Juli{\'a}n and Julien Colombelli and Jordi Llop and Samuel S{\'a}nchez",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = jan,

day = "15",

doi = "10.1038/s41565-023-01577-y",

language = "English",

volume = "19",

pages = "554--564",

journal = "Nature Nanotechnology",

issn = "1748-3387",

number = "4",

}

Simó Costa , C, Serra-Casablancas, M, Hortelão, ACL, Carlo, VD, Garrido, SG, Plaza-García, S, Rabanal, RM, Ramos-Cabrer, P, Yagüe, B, Aguado, L, Bardia, L, Tosi, S, Vallejo, VG, Martín, A, Patino, T, Julián, E, Colombelli, J, Llop, J & Sánchez, S 2024, 'Urease-powered nanobots for radionuclide bladder cancer therapy', Nature Nanotechnology, vol. 19, no. 4, pp. 554-564. https://doi.org/10.1038/s41565-023-01577-y, https://doi.org/10.1038/s41565-023-01577-y

TY - JOUR

T1 - Urease-powered nanobots for radionuclide bladder cancer therapy

AU - Simó Costa , Cristina

AU - Serra-Casablancas, Meritxell

AU - Hortelão, A. C. L.

AU - Carlo, Valerio Di

AU - Garrido, Sandra Guallar

AU - Plaza-García, Sandra

AU - Rabanal, Rosa Maria

AU - Ramos-Cabrer, Pedro

AU - Yagüe, Balbino

AU - Aguado, Laura

AU - Bardia, Lídia

AU - Tosi, Sébastien

AU - Vallejo, Vanessa Gómez

AU - Martín, Abraham

AU - Patino, Tania

AU - Julián, Esther

AU - Colombelli, Julien

AU - Llop, Jordi

AU - Sánchez, Samuel

N1 - Publisher Copyright: © The Author(s) 2024.

PY - 2024/1/15

Y1 - 2024/1/15

N2 - Bladder cancer treatment via intravesical drug administration achieves reasonable survival rates but suffers from low therapeutic efficacy. To address the latter, self-propelled nanoparticles or nanobots have been proposed, taking advantage of their enhanced diffusion and mixing capabilities in urine when compared with conventional drugs or passive nanoparticles. However, the translational capabilities of nanobots in treating bladder cancer are underexplored. Here, we tested radiolabelled mesoporous silica-based urease-powered nanobots in an orthotopic mouse model of bladder cancer. In vivo and ex vivo results demonstrated enhanced nanobot accumulation at the tumour site, with an eightfold increase revealed by positron emission tomography in vivo. Label-free optical contrast based on polarization-dependent scattered light-sheet microscopy of cleared bladders confirmed tumour penetration by nanobots ex vivo. Treating tumour-bearing mice with intravesically administered radio-iodinated nanobots for radionuclide therapy resulted in a tumour size reduction of about 90%, positioning nanobots as efficient delivery nanosystems for bladder cancer therapy.

AB - Bladder cancer treatment via intravesical drug administration achieves reasonable survival rates but suffers from low therapeutic efficacy. To address the latter, self-propelled nanoparticles or nanobots have been proposed, taking advantage of their enhanced diffusion and mixing capabilities in urine when compared with conventional drugs or passive nanoparticles. However, the translational capabilities of nanobots in treating bladder cancer are underexplored. Here, we tested radiolabelled mesoporous silica-based urease-powered nanobots in an orthotopic mouse model of bladder cancer. In vivo and ex vivo results demonstrated enhanced nanobot accumulation at the tumour site, with an eightfold increase revealed by positron emission tomography in vivo. Label-free optical contrast based on polarization-dependent scattered light-sheet microscopy of cleared bladders confirmed tumour penetration by nanobots ex vivo. Treating tumour-bearing mice with intravesically administered radio-iodinated nanobots for radionuclide therapy resulted in a tumour size reduction of about 90%, positioning nanobots as efficient delivery nanosystems for bladder cancer therapy.

KW - Cell

KW - Drug-delivery

KW - Nanomotors

KW - Tissue

KW - Tumor penetration

KW - Animals

KW - Urinary Bladder Neoplasms/diagnostic imaging

KW - Mice

KW - Urease

KW - Administration, Intravesical

KW - Radioisotopes/therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=85182459825&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/85686b72-a8e5-3bc5-95a0-d4da90f208a2/

U2 - 10.1038/s41565-023-01577-y

DO - 10.1038/s41565-023-01577-y

M3 - Article

C2 - 38225356

SN - 1748-3387

VL - 19

SP - 554

EP - 564

JO - Nature Nanotechnology

JF - Nature Nanotechnology

IS - 4

ER -

Urease-powered nanobots for radionuclide bladder cancer therapy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

NEXT-GENERATION OF IMMUNOTHERAPY AGENTS BASED ON ENGINEERED NON-TUBERCULOUS MYCOBACTERIA

Cite this

Urease-powered nanobots for radionuclide bladder cancer therapy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Projects

NEXT-GENERATION OF IMMUNOTHERAPY AGENTS BASED ON ENGINEERED NON-TUBERCULOUS MYCOBACTERIA

Cite this